8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements

Abbott Laboratories filed an 8‑K (Item 9.01) on Jan 22, 2026 — furnished a press release (Exhibit 99.1)…

Filed with the SEC on January 22, 2026 · Summarized by InvestorsBot

Abbott Laboratories filed an 8‑K (Item 9.01) on Jan 22, 2026 — furnished a press release (Exhibit 99.1) and an Inline XBRL cover page (Exhibit 104). Review the press release for material announcements. 📄 $ABT #8K #SEC

8‑K signed by Philip P. Boudreau, EVP Finance & CFO, dated Jan 22, 2026. Investors: use Exhibit 99.1 for the announcement and Exhibit 104 (XBRL) for machine-readable financial data. 📊 $ABT #Abbott #Investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from ABBOTT LABORATORIES

Abbott (via Badger Merger Sub I) has an Agreement & Plan of Merger with Exact Sciences dated Nov 19, 2025…

8-K · March 23, 2026

Abbott ($ABT) closed its acquisition of Exact Sciences ($EXAS) on Mar 23, 2026.

8-K · March 23, 2026

Abbott filed an 8‑K (Item 9.01) on Mar 9, 2026 furnishing an indenture and note forms for debt: Floating…

8-K · March 9, 2026

Abbott Labs 8‑K filed 2026‑03‑09: Item 2.03 simply incorporates Item 1.01 by reference — it does not…

8-K · March 9, 2026

BREAKING: Abbott completes $20B senior notes offering to fund the Exact Sciences takeover — $ABT $EXAS…

8-K · March 9, 2026

Abbott ($ABT) filed an 8-K on Feb 26, 2026 — added Exhibit 1.1 (Pricing Agreement) and XBRL cover page.

8-K · February 26, 2026